Mizuho Securities Reiterates Buy Rating on Nektar Therapeutics (NKTR), Expects Weakness in NKTR Shares
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $35.00 price target on Nektar Therapeutics (NASDAQ: NKTR)The analyst quotes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
